Results 71 to 80 of about 16,883 (239)

Longer-term virologic outcomes on tenofovir-lamivudine-dolutegravir in second-line ART

Southern African Journal of HIV Medicine
Background: Dolutegravir in second-line antiretroviral therapy (ART) is more effective with recycled tenofovir than switching to zidovudine. However, dolutegravir resistance is more frequent in second-line compared to first-line ART.
Jennifer K. van Heerden, Ying Zhao, Claire M. Keene, Rulan Griesel, Zaayid Omar, René Goliath, Kayla Delaney, Gert van Zyl, Gary Maartens, Graeme Meintjes   +9 more
doaj   +1 more source

Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV.

New England Journal of Medicine, 2021
BACKGROUND The World Health Organization recommends dolutegravir with two nucleoside reverse-transcriptase inhibitors (NRTIs) for second-line treatment of human immunodeficiency virus type 1 (HIV-1) infection. Evidence is limited for the efficacy of this
Nicholas I. Paton, J. Musaazi, C. Kityo, S. Walimbwa, A. Hoppe, Apolo Balyegisawa, A. Kaimal, G. Mirembe, Phionah Tukamushabe, Gilbert Ategeka, J. Hakim, H. Mugerwa, A. Siika, Jesca Asienzo, B. Castelnuovo, A. Kiragga, A. Kambugu   +16 more
semanticscholar   +1 more source

Efficacy, Effectiveness, and Safety of Treatment Regimens for Histoplasmosis and Tuberculosis Coinfection in Patients With Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome: A Systematic Review With Meta‐Analysis Protocol

Health Science Reports, Volume 9, Issue 1, January 2026.
ABSTRACT Background and Aims While previous publications have briefly pointed out a few alternative therapeutic interventions for the treatment of histoplasmosis and tuberculosis coinfections in patients with Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS), there are no reviews evaluating the efficacy, effectiveness ...
Beatriz Bernava Sarinho, Inajara Rotta, Tácio de Mendonça Lima, Brígida Dias Fernandes, Patricia Melo Aguiar, Marília Berlofa Visacri   +5 more
wiley   +1 more source

Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy

Southern African Journal of HIV Medicine, 2020
Introduction: The integrase strand transfer inhibitor dolutegravir (DTG) has a high genetic barrier to resistance. Only rare cases of resistance to DTG have been reported when it is used as a component of antiretroviral therapy regimens in treatment ...
Kairoonisha Mahomed, Carole L. Wallis, Liezl Dunn, Shavani Maharaj, Gary Maartens, Graeme Meintjes   +5 more
doaj   +1 more source

HIV viral suppression in children and adolescents 2 years after transition to dolutegravir: a multicentre cohort study

AIDS (London)
Background: Treatment failure is common among children and adolescents with HIV. Antiretroviral therapy (ART) containing dolutegravir has recently been rolled out across Africa, though long-term real-world data in paediatric populations are lacking. Here,
Akash Devendra, Maurus Kohler, Motlatsi Letsika, Hape Khooa, Lipontso Motaboli, Malebanye Lerotholi, Nadine Tschumi, N. Labhardt, J. A. Brown   +8 more
semanticscholar   +1 more source

Evaluation of the Pharmacokinetics, Disposition, and Metabolism of Miricorilant, a Novel Glucocorticoid Receptor Modulator for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis in Nonclinical and Clinical Studies

The Journal of Clinical Pharmacology, Volume 66, Issue 1, January 2026.
Abstract Miricorilant is a novel selective glucocorticoid receptor (GR) modulator with mixed agonist/antagonist effects at the GR and modest antagonism at the mineralocorticoid receptor that is being developed for the treatment of metabolic dysfunction‐associated steatohepatitis.
Hazel J. Hunt, Kirsteen M. Donaldson, Jeevan R. Kunta, Joseph M. Custodio   +3 more
wiley   +1 more source

Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents [PDF]

, 2023
Hardik Chandasana, Mita Thapar, Siobhán Hayes, Mark Baker, Diana M. Gibb, Anna Turkova, Deborah Ford, Theodore Ruel, Andrew Wiznia, Lee Fairlie, Mutsa Bwakura‐Dangarembizi, Hilda Mujuru, Carmelita Alvero, Mona Farhad, Rohan Hazra, Ellen Townley, Ann M. Buchanan, Pauline Bollen, Hylke Waalewijn, Angela Colbers, David M. Burger, Edward P. Acosta, Rajendra Singh, for the IMPAACT P1093, ODYSSEY (PENTA 20) Study Teams   +23 more
openalex   +1 more source

Efficacy, safety, and tolerability of dolutegravir-based ART regimen in Durban, South Africa: a cohort study

BMC Infectious Diseases
Background Dolutegravir is an integrase strand transfer inhibitor that has been recommended for use in first-line antiretroviral regimens by the World Health Organisation and is currently being rolled out globally.
N. Hurbans, P. Naidoo
semanticscholar   +1 more source

Estimates and predictors of HIV viral non‐suppression in South African adults on antiretroviral treatment

Journal of the International AIDS Society, Volume 29, Issue 1, January 2026.
Abstract Introduction Viral suppression estimates are essential for monitoring the performance of HIV programmes. South Africa introduced dolutegravir (DTG)‐based antiretroviral therapy (ART) in 2019. We sought to generate updated estimates of viral suppression in South African adults on ART and investigate predictors of viral non‐suppression.
Haroon Moolla, Reshma Kassanjee, Jonathan Euvrard, Gary Maartens, Hans W. Prozesky, Matthew P. Fox, Catherine Orrell, Geoffrey Fatti, Frank Tanser, Gilles Wandeler, Mary‐Ann Davies, Renee de Waal, Patience Nyakato, Leigh F. Johnson, the International epidemiology Databases to Evaluate AIDS Southern Africa (IeDEA‐SA) Collaboration   +14 more
wiley   +1 more source

The association between adherence to antiretroviral therapy and viral suppression under dolutegravir‐based regimens: an observational cohort study from Uganda

Journal of the International AIDS Society
Millions of people living with HIV (PLWH) take oral antiretroviral therapy (ART), which requires a lifetime of consistent medication adherence. The relationship between adherence and poor HIV outcomes is well documented.
Zachary Wagner, Zetianyu Wang, Chad Stecher, Y. Karamagi, M. Odiit, Jessica E. Haberer, S. Linnemayr   +6 more
semanticscholar   +1 more source